

# Emmie Ho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1612756/publications.pdf>

Version: 2024-02-01

18  
papers

329  
citations

1162367

8  
h-index

887659

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

323  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive screening of anabolic steroids, corticosteroids, and acidic drugs in horse urine by solid-phase extraction and liquid chromatography–mass spectrometry. <i>Journal of Chromatography A</i> , 2006, 1120, 38-53.	1.8	99
2	High-throughput screening of corticosteroids and basic drugs in horse urine by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 825, 47-56.	1.2	33
3	Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography–mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 2595-2606.	1.9	31
4	Doping control analysis of TB-500, a synthetic version of an active region of thymosin $\beta$ 4, in equine urine and plasma by liquid chromatography–mass spectrometry. <i>Journal of Chromatography A</i> , 2012, 1265, 57-69.	1.8	30
5	High resolution accurate mass screening of prohibited substances in equine plasma using liquid chromatography – Orbitrap mass spectrometry. <i>Drug Testing and Analysis</i> , 2013, 5, 509-528.	1.6	25
6	Detection of singly- and doubly-charged quaternary ammonium drugs in equine urine by liquid chromatography/tandem mass spectrometry. <i>Analytica Chimica Acta</i> , 2012, 710, 94-101.	2.6	19
7	A duplex qPCR assay for human erythropoietin (EPO) transgene to control gene doping in horses. <i>Drug Testing and Analysis</i> , 2021, 13, 113-121.	1.6	19
8	Liquid chromatography–mass spectrometry analysis of five bisphosphonates in equine urine and plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 998-999, 1-7.	1.2	17
9	Detection of bioactive peptides including gonadotrophin-releasing factors (GnRHs) in horse urine using ultra-high performance liquid chromatography–high resolution mass spectrometry (UHPLC/HRMS). <i>Drug Testing and Analysis</i> , 2020, 12, 1274-1286.	1.6	10
10	Optimization and implementation of four duplex quantitative polymerase chain reaction assays for gene doping control in horseracing. <i>Drug Testing and Analysis</i> , 2022, 14, 1587-1598.	1.6	9
11	Long-term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometry for the purpose of doping control. <i>Drug Testing and Analysis</i> , 2022, 14, 1244-1254.	1.6	7
12	Label-free Proteomics for Discovering Biomarker Candidates for Controlling Krypton Misuse in Castrated Horses (Geldings). <i>Journal of Proteome Research</i> , 2020, 19, 1196-1208.	1.8	6
13	Label-free proteomics for discovering biomarker candidates of RAD140 administration to castrated horses. <i>Drug Testing and Analysis</i> , 2021, 13, 1034-1047.	1.6	6
14	Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high-resolution mass spectrometer for the purpose of doping control. <i>Drug Testing and Analysis</i> , 2022, 14, 233-251.	1.6	6
15	Tiludronic acid can be detected in blood and urine samples from Thoroughbred racehorses over 3 years after last administration. <i>Equine Veterinary Journal</i> , 2021, 53, 1287-1295.	0.9	4
16	A high-throughput and broad-spectrum screening method for analysing over 120 drugs in horse urine using liquid chromatography–high-resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2020, 12, 900-917.	1.6	4
17	Application of a non-target variable data independent workflow (vDIA) for the screening of prohibited substances in doping control testing. <i>Drug Testing and Analysis</i> , 2021, 13, 1008-1033.	1.6	4
18	Doping control analysis of total arsenic in equine plasma. <i>Drug Testing and Analysis</i> , 2020, 12, 1462-1469.	1.6	0